Thrive Capital: Inside Josh Kushner's $10B Fund and 15-Year Rise to VC's Elite

Thrive Capital: Inside Josh Kushner's $10B Fund and 15-Year Rise to VC's Elite

TL;DR: Bloomberg reported on February 17, 2026 that Josh Kushner's Thrive Capital closed Thrive X at over $10 billion, nearly double the $5.3 billion Thrive IX raised just 18 months earlier. The firm turned away billions in additional LP commitments. If you track venture capital at all, that single data point tells you something important: Thrive is no longer a scrappy New York upstart. It is one of the most sought-after VC franchises on Earth, with $22.3 billion raised across all funds and total AUM exceeding $50 billion.

You cannot invest in Thrive Capital directly unless you are an institution or a high-net-worth limited partner with the right relationships. But you can study exactly how Josh Kushner built this franchise, understand what his portfolio tells you about the next decade of technology, and identify the legal paths that get you adjacent exposure. That is what this piece does.

Who Josh Kushner Is and Why His Background Matters

Josh Kushner graduated from Harvard with a government degree in 2008, spent time as a Goldman Sachs analyst in distressed debt, and then returned to Harvard Business School. He was 24 years old when he raised his first $5 million fund in 2009. Joel Cutler of General Catalyst backed him. That is the origin story.

What makes Kushner unusual is that he did not just write checks. He built companies. He co-founded Oscar Health in 2012 alongside Mario Schlosser and Kevin Nazemi, creating a technology-driven health insurance carrier from scratch. He co-founded Cadre in 2015, a real estate investment platform. He built Thrive Holdings as a permanent capital vehicle to acquire and consolidate businesses using AI. This is a founder, not purely a financier. That distinction shapes how the firm operates.

Today Kushner owns 96.7% of Thrive Capital's management company. In 2023, a group that included Bob Iger, Henry Kravis, Mukesh Ambani, Xavier Niel, and Jorge Paulo Lemann purchased a 3.3% stake, valuing the firm itself at $5.3 billion. The firm operates from the Puck Building in New York City with a team of 64 people, nine of whom make investment decisions. Kushner, at 40, is the oldest person on the investment team.

The Fund History: $5M to $10B in 15 Years

This table is the clearest way to see what actually happened at Thrive Capital. The growth curve is staggering:

Fund	Year	Size	Net TVPI (Est.)
Fund I	2009	$5M	N/A
Fund II	2011	$40M	~5.7x
Fund III	2012	$150M	~6.1x
Fund IV	2014	$400M	~5.4x
Fund V	2016	$700M	~3.5x
Fund VI	2018	$1B	N/A
Fund VII	2021	$2B	N/A
Fund VIII	2022	$3B	126%+ IRR reported
Fund IX	2024	$5.3B	34.5% net IRR (IX Growth, est.)
Thrive X	2026	$10B+	Too early

Funds II through V averaged approximately 4.5x net TVPI. Those vintage vehicles, all under $800 million, produced the returns that built Thrive's reputation. Fund III alone achieved an estimated 6.1x net TVPI on a $150 million vehicle. The Fund VIII reported IRR exceeding 126% is driven by early positions in OpenAI, Databricks, Cursor, and Ramp.

The doubling from $5.3 billion to $10 billion in a single fundraising cycle is the headline number. But I want you to think carefully about what that means for returns. I address that tension directly in the risk section below.

The Investment Thesis: Concentrated, High-Conviction, AI-First

Thrive backs 8 to 12 new companies per year across all stages. That is a deliberately low number. The firm writes large checks and holds through multiple rounds rather than selling early. You get the same partner from Series A through growth. No handoffs, no internal champion rotation. That structural choice matters for founders, and it matters for the returns Thrive captures from compounding ownership in breakout companies.

The thesis sits on three pillars. First, category-defining technology that reshapes existing industries at the platform level. Not incremental upgrades, but structural changes in fintech, healthcare, software infrastructure, and consumer behavior. Stripe at a $3.6 billion valuation in 2014 fits that model. Robinhood fits that model. Oscar Health fits that model.

Second, an AI-first worldview that crystallized in 2021 and 2022. OpenAI is the centerpiece, but the portfolio now spans foundation models (OpenAI, Anthropic), AI infrastructure (Databricks, Scale AI), and the application layer (Anysphere/Cursor, ElevenLabs, Physical Intelligence).

Third, founder proximity. Josh Kushner is himself a builder. That creates a different conversation in the boardroom than a pure capital allocator can have. Thrive's thesis on founder relationships has consistently attracted companies that could raise from anyone.

The OpenAI Bet: Anatomy of a Decade-Long Relationship

This is the story inside the story. Thrive first invested $130 million in OpenAI in 2022 at a $29 billion valuation. Then, in October 2024, Thrive led OpenAI's $6.6 billion fundraising round, putting in approximately $1.3 billion at a $157 billion valuation, according to TechCrunch. Two months later, in December 2024, CNBC reported that Thrive invested another $1 billion in OpenAI at a $285 billion valuation.

Then the relationship inverted. In December 2025, OpenAI took an equity stake in Thrive Holdings. The venture firm is now simultaneously a major OpenAI LP and a company in which OpenAI holds equity. That structure — VC firm as strategic operating partner rather than passive capital provider — is genuinely new. Thrive Holdings uses that relationship to deploy AI automation across the traditional services businesses it acquires.

For Fund VIII investors, that original $130 million OpenAI position at $29 billion valuation has grown to sit on a company now valued at multiples of that entry point. That is the primary driver behind the reported 126%+ IRR for that vintage.

Key Exits and Active Positions Worth Watching

Oscar Health (NYSE: OSCR). Kushner co-founded Oscar in 2012. At the March 2021 IPO, SEC filings show Thrive Capital and Kushner beneficially owned 16% of outstanding stock and held 75.4% of voting power. Oscar posted its first profitable year in 2024, reporting $25.4 million net income on $9.2 billion in revenue. The 2025 revenue guidance is $11.2 billion to $11.3 billion. In 2024, Kushner personally purchased roughly $20 million in OSCR shares, the first insider purchase since the IPO. That is not a founder cashing out. That is a founder doubling down.

Cursor/Anysphere. Thrive led early rounds in Anysphere, the company behind Cursor, the AI coding assistant that reached $2 billion in annual recurring revenue in early 2026. In April 2026, Bloomberg reported that SpaceX has agreed to acquire Anysphere for up to $60 billion. If that deal closes, Thrive stands to realize one of the largest M&A exits in AI application history from what began as a relatively modest Series A position.

Stripe. Thrive first backed Stripe in 2014 at a $3.6 billion valuation. In 2023, the firm raised a dedicated $1.8 billion special purpose vehicle to invest in Stripe at a $50 billion valuation. Stripe's current estimated valuation sits above $140 billion. No IPO date is set, but Stripe represents one of Thrive's largest unrealized positions.

Historic exits. Thrive participated in Instagram's Series B at a $500 million valuation. Facebook announced the acquisition within days. The firm held approximately 9-10% of GitHub when Microsoft acquired it for $7.5 billion in 2018. Twitch, Spotify, Affirm, Nubank, and Robinhood all produced public market exits in the 2018 to 2021 window. Ten Thrive portfolio companies went public in 2021 alone.

What You Can Learn from Thrive's Moves, Even Without Access

You cannot commit capital to Thrive X. Access is restricted to institutions and high-net-worth limited partners with existing relationships. That is the reality, and I am not going to pretend otherwise.

But Thrive's portfolio sends clear signals you can act on. Here is what I read from the thesis.

Follow the AI application layer, not just the model layer. Thrive's highest-velocity returns in Fund VIII came from Cursor, Ramp, and Databricks, not just OpenAI. The application layer companies with real revenue (Cursor at $2 billion ARR; Ramp at a $13.3 billion valuation) are where conviction is being rewarded. Public market equivalents include companies building on top of foundation models rather than competing with them.

Ownership concentration rewards patience. Thrive did not sell Stripe at a 3x. It did not sell OpenAI at 5x. The returns that built Thrive's reputation came from holding through multiple rounds. If you have positions in early-stage technology companies, or even public market equivalents, the Thrive playbook argues for resisting the impulse to rotate too early.

Watch the Oscar Health playbook for insurtech. Oscar reported its first profitable year in 2024 after more than a decade of losses. The model of technology-driven health insurance with a better consumer experience is now working. Read our full analysis of insurtech investing opportunities for context on where the public markets are pricing this sector today.

Secondaries markets and BDC co-investment. For accredited investors who want economic exposure to pre-IPO names in Thrive's portfolio, the secondary market for private shares has expanded significantly. Platforms handling direct secondary transactions in companies like Stripe, SpaceX, and Databricks allow accredited investors to buy existing shareholder positions, typically at a discount to the last primary round valuation. Business development companies (BDCs) that co-invest alongside major VC firms also offer registered security exposure to late-stage private credit and equity. Our guide to secondary market investing for accredited investors covers the mechanics and current pricing dynamics.

You can also track Thrive's publicly traded portfolio companies directly. Oscar Health (NYSE: OSCR), Nubank (NYSE: NU), Warby Parker (NYSE: WRBY), and Robinhood (NASDAQ: HOOD) are all accessible in a standard brokerage account. See our comparison of Thrive-linked public equities for current valuations and analyst consensus.

The Risk Picture: What the Fund Size Doubling Actually Means

I said I would address the tension in the fund size numbers, and here it is. Funds II through V averaged 4.5x net TVPI on vehicles under $800 million. Thrive X is deploying $10 billion from a single fund. The math is unforgiving: to achieve a 4x return on $10 billion, Thrive needs to generate $40 billion in realized and unrealized value from roughly 12 to 15 core positions.

The marquee positions in Thrive X were acquired at historically elevated entry valuations. OpenAI at $285 billion. SpaceX at a post-xAI merger valuation near $1.25 trillion. Stripe above $140 billion. These are not seed-stage bets. They are growth bets on companies already priced for near-perfect execution. Exit multiples from these entry points require IPO windows, sustained revenue growth, and macro conditions that do not yet exist.

There is also concentration risk. A single meaningful markdown hits fund-level returns hard when you are running 12 positions at $10 billion. A failed OpenAI IPO, competitive displacement in AI coding, or a regulatory action affecting Oscar Health's ACA market business each represents that kind of event risk.

Key-person risk is real. Josh Kushner owns 96.7% of the management company. Succession planning at a 64-person firm that has grown to this scale remains opaque to outside observers. And the Thrive Holdings pivot toward permanent capital and AI-enabled roll-up acquisitions represents a different risk-return profile than the venture strategy that built the brand. Limited partners who subscribed to one type of exposure may find the portfolio characteristics shifting.

None of this means Thrive X will fail to generate strong returns. It means the conditions required for strong returns are more specific, and more dependent on external variables, than they were when Thrive was deploying $150 million. That is always true as a fund scales. Understand it before you benchmark your own portfolio against Thrive's early-vintage track record.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.